Lakshmi A. Devi, Ph.D.

Dr. Lakshmi Devi is a Professor of Pharmacological Sciences, Neuroscience and Psychiatry at the Icahn School of Medicine at Mount Sinai, New York. Dr. Devi received her Ph.D. from the University of Windsor in Ontario, Canada. She obtained her postdoctoral training at the Addiction Research Foundation in Palo Alto, California and at the Vollum Institute in Portland, Oregon. She was recruited as an Assistant Professor of Pharmacology to New York University and in 2002 as Professor of Pharmacology and Biological Sciences to the Mount Sinai School of Medicine. Dr. Devi serves as the Director of the Interdisciplinary postdoctoral training program in drug abuse research and also as the Dean for Academic Development and Enrichment at the Icahn School of Medicine at Mount Sinai. Dr. Devi's current research interests include uncovering novel molecular mechanisms of opioid receptor signaling in analgesia and addiction, identifying opiate-induced change in the synaptic protein interaction networks, and discovering new neuropeptides & characterizing their receptors.

Dr. Devi is actively involved in several professional societies. She served as the President of the International Narcotics Research Conference from 2006-2010, Secretary/Treasurer of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics from 2013-2015, a member of the board of directors of the Winter Conference on Brain Research from 2014-2017. Dr. Devi is currently the Chair of the Mentoring and Career Development Committee of the American Society for Pharmacology and Experimental Therapeutics. Among her many awards are the Senior Scientist Research and Mentorship Award, National Institutes of Health MERIT Award, 2016 INRC Founders' Lectureship and 2018 WCBR Pioneer Award. Dr. Devi is an elected Fellow of AAAS. She has authored more than 200 scientific research articles and reviews in the fields of molecular pharmacology of receptors in the reward pathway and identification of therapeutics targeting these receptors.